|
Indications and Dosage
Endotracheal
Neonatal respiratory distress syndrome Child: Premature neonates ≥700 g: Initially, 100 mg phospholipids/kg (4 mL/kg) given as soon as possible, preferably w/in 15 min of birth (as prophylaxis); or as soon as diagnosis of RDS is made, preferably w/in 8 hr of birth (as treatment). May repeat no more frequently than 6 hrly w/in 1st 48 hr of life up to a Max of 4 doses if there is evidence of continuing distress.
|
|
Special Precautions
Childn.
|
|
Adverse Reactions
Significant: Transient bradycardia and oxygen desaturation, nosocomial sepsis, endotracheal tube obstruction.
Nervous: Seizures, intracranial haemorrhage. CV: Hypotension, HTN, tachycardia, ventricular tachycardia, aortic thrombosis, cardiac failure, cardio-respiratory arrest, increased apical pulse, persistent foetal circulation, air embolism, total anomalous pulmonary venous return. GI: Abdominal distention, haemorrhage, intestinal perforations, volvulus, bowel infarct, feeding intolerance, stress ulcer. Resp: Pulmonary haemorrhage, apnoea, emphysema, hypo- and hypercapnia, subglottic stenosis, paralyzed diaphragm, resp failure. Hepatic: Hepatic failure. Genitourinary: Renal failure, haematuria. Endocrine: Adrenal haemorrhage, hyperphosphataemia. Haematologic: Coagulopathy, thrombocytopenia, disseminated intravascular coagulation. Musculoskeletal: Inguinal hernia. Others: Fever, deterioration. |
|
MonitoringParameters
Monitor continuous ECG and arterial or transcutaneous measurement of systemic oxygen and CO2 during admin, and arterial blood gases.
|
|
Action
Description: Beractant, a modified pulmonary surfactant, is a bovine lung extract of phospholipids. It replaces deficient or ineffective endogenous lung surfactant in neonates w/ resp distress syndrome (RSD). An efficient surfactant lowers surface tension between air and alveolar surface, hence preventing the alveoli to collapse during expiration.
Onset: Improved oxygenation: W/in minutes. Pharmacokinetics: Distribution: Rapidly distributes to the alveolar surfaces. Excretion: |
|
Storage
Store between 2-8°C. Do not freeze. Protect from light.
|
|
MIMS Class
|
|
References
Anon. Beractant. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 05/05/2017. Buckingham R (ed). Pulmonary Surfactants. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 05/05/2017. McEvoy GK, Snow EK, Miller J et al (eds). Beractant. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 05/05/2017. Survanta Suspension (AbbVie Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 05/05/2017.
|
Manage Account
Change Password
Sign Out
